SARTORIUS AG, DE0007165631

Sartorius releases Annual Report for 2025

16.02.2026 - 09:08:53 | dgap.de

SARTORIUS AG / DE0007165631

SARTORIUS AG / Key word(s): Annual Report
(news with additional features)

16.02.2026 / 09:08 CET/CEST
The issuer is solely responsible for the content of this announcement.


Göttingen, Germany | February 16, 2026



The life science group Sartorius today released its Annual Report for 2025. The document is available at the following link: https://www.sartorius.com/ar2025



Financial calendar
March 26,2026 | Annual General Meeting 
April 23,2026 | Publication of the first quarter results for January to March 2026 
July 23,2026 | Publication of half-year results for January to June 2026 
October 22,2026 | Publication of nine-month results for January to September 2026  


A profile of Sartorius
Sartorius is a leading international partner to the biopharmaceutical research and manufacturing industries. The Lab Products & Services Division focuses on innovative laboratory instruments and consumables for research and quality assurance laboratories in pharmaceutical and biopharmaceutical companies as well as academic research institutions. The Bioprocess Solutions Division supports customers with a broad product portfolio focused on single-use solutions for the safer, faster, and more sustainable production of biotech drugs, vaccines, and cell and gene therapies. With around 60 production and sales locations worldwide, the Göttingen-based company has a strong global presence. Sartorius regularly supplements its portfolio with acquisitions of complementary technologies. In 2025, the company generated sales revenue of around 3.5 billion euros. More than 14,000 employees serve customers around the globe. 
 
Visit our newsroom and follow us on LinkedIn.  


Contact
Verena Sattel 
External Communications 
+49 551 308 9261 
verena.sattel@sartorius.com 

Additional features:

File: | Media Release


16.02.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News
Language: English
Company: SARTORIUS AG
Otto-Brenner-Straße 20
37079 Göttingen
Germany
Phone: +49.(0)551-308.0
Fax: +49.(0)551-308.3289
E-mail: info@sartorius.com
Internet: www.sartorius.com
ISIN: DE0007165631, DE0007165607
WKN: 716563, 716560
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate BSX
EQS News ID: 2275076

 
End of News EQS News Service

2275076  16.02.2026 CET/CEST

So schätzen die Börsenprofis SARTORIUS AG Aktien ein!

<b>So schätzen die Börsenprofis SARTORIUS AG Aktien ein!</b>
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen – dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren.
Für. Immer. Kostenlos.
DE0007165631 | SARTORIUS AG | boerse | 68584664 |